Head of Mood Disorders Psychopharmacology Unit,
University Health Network and Professor of Psychiatry and Pharmacology,
University of Toronto
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry, Visiting Professor, College of Medicine, University of the Philippines, Manila, Philippines and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE) and the CEO of Braxia Scientific Corp. Dr. McIntyre is also a Fellow of the American Psychiatric Association (APA).
Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, and 2022 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has authored/co-authored more than 900 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre has also contributed extensively to clinical practice guidelines. For example, Dr. McIntyre is the lead author the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. In addition, Dr. McIntyre is also the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders as well as the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
“I am on DBSA’s board because I am grateful and so privileged to have met so many people and families affected by depression and bipolar disorder, and have witnessed the resiliency and the amazing opportunities that can be successfully achieved when the medical profession works in unison with people who are affected by depression.”